| Title |
Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, October 2021
|
| DOI | 10.2147/ceor.s328433 |
| Pubmed ID | |
| Authors |
Bhavani Shankara Bagepally, Usa Chaikledkaew, Sitaporn Youngkong, Thunyarat Anothaisintawee, Montarat Thavorncharoensap, Charungthai Dejthevaporn, Ammarin Thakkinstian |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 8% |
| Student > Doctoral Student | 2 | 6% |
| Researcher | 2 | 6% |
| Student > Postgraduate | 2 | 6% |
| Student > Ph. D. Student | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 21 | 58% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 11% |
| Medicine and Dentistry | 3 | 8% |
| Social Sciences | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Business, Management and Accounting | 1 | 3% |
| Other | 4 | 11% |
| Unknown | 21 | 58% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2021.
All research outputs
#17,350,971
of 25,462,162 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#331
of 525 outputs
Outputs of similar age
#264,472
of 437,005 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#6
of 9 outputs
Altmetric has tracked 25,462,162 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,005 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.